[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a sale of 13,712 shares of the issuer's common stock on 08/13/2025 at a price of $15.00 per share. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. After the reported transaction, the reporting person beneficially owned 19,631 shares, which includes an aggregate 1,778 shares acquired under the issuer's Employee Stock Purchase Plan in one or more transactions exempt under Rules 16b-3(c) and 16b-3(d). The form is signed and dated 08/15/2025.

Positive

• Transaction executed under a Rule 10b5-1 trading plan, which documents pre-established trading intent
• Disclosure includes ESPP share detail (1,778 shares) clarifying part of the remaining holdings
• Form is signed and dated, meeting filing formalities

Negative

• Reporting person reduced direct holdings by 13,712 shares, a material disposition relative to individual position size
• No derivative activity disclosed to offset the reported disposition (options or other instruments not reported)

Insights

Securities Analyst

TL;DR: Routine insider sale under a pre-established 10b5-1 plan; no derivative activity reported.

The Form 4 discloses a direct disposition of 13,712 common shares at $15.00 executed under a Rule 10b5-1 plan adopted December 12, 2024. The filing reports remaining beneficial ownership of 19,631 shares, which includes 1,778 ESPP shares acquired in exempt transactions. There are no option exercises or other derivative transactions reported. For investors, this is a documented, planned sale by a senior officer rather than an ad hoc disposition; the filing contains clear transaction dates, prices, and the plan adoption date relevant for compliance review.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 10b5-1 and Section 16 reporting; timing and plan adoption are clearly stated.

The report identifies the reporting person as an officer and discloses that the sale was made pursuant to a 10b5-1 trading plan adopted on December 12, 2024, which supports the affirmative defense against insider trading claims. The Form 4 also notes ESPP-acquired shares included in total holdings and provides a manual signature dated August 15, 2025. No amendments or additional related-party filings are indicated in the document. From a governance perspective, the form contains the required information to evaluate procedural compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S(1)		13,712	D	$15	19,631(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The reported total includes an aggregate 1,778 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

	/s/ Jonathan Allan	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jonathan Allan report on Form 4 for STOK?

The Form 4 reports a sale of 13,712 shares of Stoke Therapeutics common stock on 08/13/2025 at $15.00 per share, leaving 19,631 shares beneficially owned.

Was the insider sale by Jonathan Allan part of a 10b5-1 plan?

Yes. The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

How many shares remaining include ESPP purchases?

The reported total beneficial ownership of 19,631 shares includes an aggregate of 1,778 shares acquired under the issuer's Employee Stock Purchase Plan.

Were any options, warrants, or other derivatives reported in this Form 4?

No. Table II (derivative securities) shows no entries; the filing contains only a non-derivative sale of common stock.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by the reporting person and dated 08/15/2025.